Conclusions  by Acar, Jacques
Conclusions 
Jacques Acar  
Department of Medical Microbiology, UFR Broussais-Hotel-Dieu, Universitt- Pierre et Marie Curie,  
Paris. France 
The microbiology group concluded that Streptococcur 
pneumoniae and Haemophilus ivlfluenzae are the most 
important pathogens which have to be eradicated 
in respiratory tract infections. There are quite large 
differences in activity between the current antimicrobial 
agents used for treatment and they showed that the new 
fluoroquinolones have good activity against respiratory 
tract pathogens, including intracellular pathogens, 
2nd S. pneumoniae. Thus, the spectrum of activity of 
the new fluoroquinolones is adapted to respiratory 
infections. 
The resistance group showed that trends in 
increasing resistance among respiratory pathogens are 
opening the way for a broader use of fluoroquinolones. 
For example, a Hmmophilus strain which does not 
respond to macrolides, or p-lactams, will need a 
fluoroquinolone. Primary mutants are the key issue for 
the development of resistance to fluoroquinolones, 
because the detection of the such mutants and the 
proper use of fluoroquinolones able to eliminate early 
resistant variants may reduce the development of 
resistance in the future. At present, despite the use of 
ofloxacin and ciprofloxacin, there is little resistance 
to the fluoroquinolones in respiratory pathogens, 
indicating that the selection pressure has not been 
strong enough. 
The pharmacokinetics and pharmacodynamics 
group showed how the differences in pharmacokinetics 
and pharmacodynaniics between the various fluoro- 
quinolones, such as metabolism and elimination by 
the kidney or by the liver, should be used as a tool to 
understand variations in clinical results with different 
fluoroquinolones. An important aspect is the dose 
schedule in order to prevent the selection of resistant 
strains. In clinical studies, dosing and particularly the 
MIC should be taken into account. 
The lower respiratory tract infection group reached 
a consensus that the new fluoroquinolones are more 
active against S. pmumoniae and can be considered as a 
suitable treatment for lower respiratory tract infections, 
including possible first-line treatment. The importance 
of the step-down therapy from intravenous to oral was 
emphasized, along with the need for future clinical 
studies to be performed to optimize the duration of 
treatment in lower respiratory tract infections. 
The upper respiratory tract infection group con- 
cluded that there is no role for fluoroquinolones 
in pharyngitis. In addition, as they are not currently 
licensed for pediatrics, their use in acute otitis media is 
limited. However, in the future, they may be useful in 
this indication because of the high numbers of strains 
resistant to currently used antibiotics. Fluoroquinolones 
can be used in acute sinusitis in adults but more studies 
are needed. 
To summarize, the meeting has contributed to 
our knowledge and understanding of the new fluoro- 
quinolones and their clinical indications in the treat- 
ment of respiratory tract infections. It is clear that these 
agents do form a new class of ‘respiratory fluoro- 
quinolones’ with their improved activity against the 
major respiratory pathogens. Further clinical studies are 
required to clarify issues such as dosing and duration of 
treatment and to confirm their indications in lower and 
upper respiratory tract infections and their possible 
future use in children. 
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